{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:07:28Z","timestamp":1775822848193,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04860-x","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:43:16Z","timestamp":1772642596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Roxadustat induced fetal hemoglobin in anemic CKD patients: a dual-center real-world observational cohort study"],"prefix":"10.1186","volume":"27","author":[{"given":"Wanling","family":"Gou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengning","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanyue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangzhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoting","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanni","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"4860_CR1","doi-asserted-by":"publisher","unstructured":"Voit RA, Sankaran VG. Stabilizing HIF to ameliorate anemia Cell. 2020;180(1). https:\/\/doi.org\/10.1016\/j.cell.2019.12.010.","DOI":"10.1016\/j.cell.2019.12.010"},{"key":"4860_CR2","doi-asserted-by":"publisher","unstructured":"Luo Z, Tian M, Yang G, Tan Q, Chen Y, Li G, et al. Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. Signal Transduct Targeted Ther. 2022;7(1). https:\/\/doi.org\/10.1038\/s41392-022-01080-1.","DOI":"10.1038\/s41392-022-01080-1"},{"key":"4860_CR3","doi-asserted-by":"publisher","unstructured":"Zhu X, Jiang L, Wei X, Long M, Du Y. Roxadustat: not just for anemia. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.971795.","DOI":"10.3389\/fphar.2022.971795"},{"key":"4860_CR4","doi-asserted-by":"publisher","unstructured":"Lu X, Qinglin H, YangChen M, Bing C, H. Efficacy and safety of roxadustat in the treatment of refractory non-severe aplastic anemia. Chin J Hematol. 2024;45(3). https:\/\/doi.org\/10.3760\/cma.j.cn121090-20230902-00101.","DOI":"10.3760\/cma.j.cn121090-20230902-00101"},{"key":"4860_CR5","doi-asserted-by":"publisher","unstructured":"Henry DH, Glaspy J, Harrup R, Mittelman M, Zhou A, Carraway HE, et al. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: open-label, dose-selection, lead-in stage of a phase 3 study. Am J Hematol. 2021;97(2).https:\/\/doi.org\/10.1002\/ajh.26397.","DOI":"10.1002\/ajh.26397"},{"key":"4860_CR6","doi-asserted-by":"publisher","unstructured":"At T, Km M, Md C. Guidelines for the management of non-transfusion-dependent \u03b2-Thalassaemia. In: Br J Haematol. 3rd. Nicosia (Cyprus): Thalassaemia International; 2023. https:\/\/doi.org\/10.1111\/bjh.70047.","DOI":"10.1111\/bjh.70047"},{"key":"4860_CR7","doi-asserted-by":"publisher","unstructured":"Zertal-Zidani S, Ducrocq R, Sahbatou M, Satta D, Krishnamoorthy R. Foetal haemoglobin in normal healthy adults: relationship with polymorphic sequences cis to the \u03b2 globin gene. Eur J Hum Genet. 2002;10(5). https:\/\/doi.org\/10.1038\/sj.ejhg.5200809.","DOI":"10.1038\/sj.ejhg.5200809"},{"key":"4860_CR8","doi-asserted-by":"publisher","unstructured":"Mutua B, Chelangat R, Mustafa B, Were T, Makani J, Sowayi G, et al. High-performance liquid chromatography local reference ranges of hemoglobin fractions (HbA, HbA2, and HbF) in detection of hemoglobinopathies in western Kenya. Egypt J Intern Med. 2022;34(1). https:\/\/doi.org\/10.1186\/s43162-022-00187-9.","DOI":"10.1186\/s43162-022-00187-9"},{"key":"4860_CR9","doi-asserted-by":"publisher","unstructured":"Kattamis A, Kwiatkowski JL, Aydinok Y. Thalassaemia. Lancet. 2022;399(10343):2310-2324. https:\/\/doi.org\/10.1016\/s0140-6736(22)00536-0.","DOI":"10.1016\/s0140-6736(22)00536-0"},{"key":"4860_CR10","doi-asserted-by":"publisher","unstructured":"Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. J Hematol Oncol. 2022;15(1):20. https:\/\/doi.org\/10.1186\/s13045-022-01237-z.","DOI":"10.1186\/s13045-022-01237-z"},{"issue":"April","key":"4860_CR11","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood.V63.4.921.921","volume":"Vol. 63 No. 4","author":"BDR Powars","year":"1984","unstructured":"Powars BDR, Weiss JN, Chan LS. W.A.Schroeder: is there a threshold when sickle the cell hemoglobin threshold morbidity patients average? Blood. 1984 Apr;63(4):921\u201326.","journal-title":"Blood"},{"key":"4860_CR12","doi-asserted-by":"publisher","unstructured":"Estepp JH, Smeltzer MP, Kang G, Li C, Wang WC, Abrams C, et al. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Am J Hematol. 2017;92(12):1333-1339. https:\/\/doi.org\/10.1002\/ajh.24906.","DOI":"10.1002\/ajh.24906"},{"key":"4860_CR13","doi-asserted-by":"publisher","unstructured":"Hebert N, Rakotoson MG, Bodivit G, Audureau E, Bencheikh L, Kiger L, et al. Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease. Am J Hematol. 2020;95(11). https:\/\/doi.org\/10.1002\/ajh.25937.","DOI":"10.1002\/ajh.25937"},{"key":"4860_CR14","doi-asserted-by":"publisher","unstructured":"Feng RP, Mayuranathan T, Huang P, Doerfler PA, Li YC, Yao Y, et al. Activation of \u03b3-globin expression by hypoxia-inducible factor 1\u03b1. Nature. 2022;610(7933). https:\/\/doi.org\/10.1038\/s41586-022-05312-w.","DOI":"10.1038\/s41586-022-05312-w"},{"key":"4860_CR15","doi-asserted-by":"publisher","unstructured":"Sharma M, Lequang T, Philips BJ, Chowdhury FA, Wood KC, Straub AC, et al. Inhibition of hypoxia inducible factor prolyl hydroxylase by FG-4592 (Roxadustat) increases erythropoietic stimulation in a mouse model of sickle cell disease. Blood. 2022;140, Supplement, 1:5391-5392. https:\/\/doi.org\/10.1182\/blood-2022-164803.","DOI":"10.1182\/blood-2022-164803"},{"key":"4860_CR16","doi-asserted-by":"publisher","unstructured":"Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, et al. HIF-prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007;110(6):2140-2147. https:\/\/doi.org\/10.1182\/blood-2007-02-073254.","DOI":"10.1182\/blood-2007-02-073254"},{"key":"4860_CR17","doi-asserted-by":"publisher","unstructured":"Ubaid S, Kashif M, Laiq Y, Nayak AK, Kumar V, Singh V. Targeting HIF-1\u03b1 in sickle cell disease and cancer: unraveling therapeutic opportunities and risks. Expert Opin Ther Targets. 2024;28(5):357-373. https:\/\/doi.org\/10.1080\/14728222.2024.2367640.","DOI":"10.1080\/14728222.2024.2367640"},{"key":"4860_CR18","doi-asserted-by":"publisher","unstructured":"Deng W, Rupon Jeremy W, Krivega I, Breda L, Motta I, Jahn Kristen S, et al. Reactivation of developmentally silenced globin genes by forced chromatin looping. Cell. 2014;158(4):849-860. https:\/\/doi.org\/10.1016\/j.cell.2014.05.050.","DOI":"10.1016\/j.cell.2014.05.050"},{"key":"4860_CR19","doi-asserted-by":"publisher","unstructured":"K E, H P, P SA, S M, A O, G BM, et al. Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts. Blood. 2020 May, 28;135(22):1957-1968. https:\/\/doi.org\/10.1182\/blood.2020005058.","DOI":"10.1182\/blood.2020005058"},{"key":"4860_CR20","doi-asserted-by":"publisher","unstructured":"Gupta P, Goswami SG, Kumari G, Saravanakumar V, Bhargava N, Rai AB, et al. Development of pathophysiologically relevant models of sickle cell disease and \u03b2-thalassemia for therapeutic studies. Nat Commun. 2024;15(1). https:\/\/doi.org\/10.1038\/s41467-024-46036-x.","DOI":"10.1038\/s41467-024-46036-x"},{"key":"4860_CR21","unstructured":"Longitudinal Data Analysis. In: Fitzmaurice G, Davidian M, Verbeke G, & Molenberghs G, editors. Chapman and Hall\/CRC. 1st. 2008. p. 79\u2013106."},{"key":"4860_CR22","doi-asserted-by":"publisher","unstructured":"Huangchao J, Xuewei L, Yantao J, Qianlei X, Pengyu L, Yanmin M, et al. The effect of traditional Chinese Medicine on the Long-term change of CD4+ T lymphocyte count in HIV-infected patients based on the Linear mixed effects model. Chin J Dermatovenereology. 2024;38:200-208. https:\/\/doi.org\/10.13735\/j.cjdv.1001-7089.202309021.","DOI":"10.13735\/j.cjdv.1001-7089.202309021"},{"key":"4860_CR23","doi-asserted-by":"publisher","unstructured":"Hart SE, Brown DL, Kim HM, Qi J, Hamill JB, Wilkins EG. Association of clinical complications of chemotherapy and patient-reported outcomes after immediate breast reconstruction. JAMA Surg. 2021;156(9):847-855. https:\/\/doi.org\/10.1001\/jamasurg.2021.2239.","DOI":"10.1001\/jamasurg.2021.2239"},{"key":"4860_CR24","doi-asserted-by":"publisher","unstructured":"Bou-Fakhredin R, De Franceschi L, Motta I, Cappellini MD, Taher AT. Pharmacological induction of fetal hemoglobin in \u03b2-thalassemia and sickle cell disease: an updated perspective. Pharmaceuticals. 2022;15(6). https:\/\/doi.org\/10.3390\/ph15060753.","DOI":"10.3390\/ph15060753"},{"key":"4860_CR25","doi-asserted-by":"publisher","unstructured":"Pule GD, Mowla S, Novitzky N, Wiysonge CS. Wonkam A: a systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Rev Hematol. 2015;8(5):669-679. https:\/\/doi.org\/10.1586\/17474086.2015.1078235.","DOI":"10.1586\/17474086.2015.1078235"},{"key":"4860_CR26","doi-asserted-by":"publisher","unstructured":"Fernandez-Zapico M, Shearstone JR, Golonzhka O, Chonkar A, Tamang D, van Duzer JH, et al. Chemical Inhibition of histone Deacetylases 1 and 2 induces fetal hemoglobin through Activation of GATA2. PLoS One. 2016;11(4). https:\/\/doi.org\/10.1371\/journal.pone.0153767.","DOI":"10.1371\/journal.pone.0153767"},{"key":"4860_CR27","doi-asserted-by":"publisher","unstructured":"McArthur JG, Svenstrup N, Chen C, Fricot A, Carvalho C, Nguyen J, et al. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2020;105(3):623-631. https:\/\/doi.org\/10.3324\/haematol.2018.213462.","DOI":"10.3324\/haematol.2018.213462"},{"key":"4860_CR28","doi-asserted-by":"publisher","unstructured":"Ren Q, Zhou Y-L, Wang L, Chen Y-S, Ma Y-N, Li P-P, et al. Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Ann Hematol. 2018;97(10):1933-1939. https:\/\/doi.org\/10.1007\/s00277-018-3395-5.","DOI":"10.1007\/s00277-018-3395-5"},{"key":"4860_CR29","doi-asserted-by":"publisher","unstructured":"Chen J-M, Zhu W-J, Liu J, Wang G-Z, Chen X-Q, Tan Y, et al. Safety and efficacy of thalidomide in patients with transfusion-dependent \u03b2-thalassemia: a randomized clinical trial. Signal Transduct Targeted Ther. 2021;6(1). https:\/\/doi.org\/10.1038\/s41392-021-00811-0.","DOI":"10.1038\/s41392-021-00811-0"},{"key":"4860_CR30","doi-asserted-by":"publisher","unstructured":"DeSimone J, Koshy M, Dorn L, Lavelle D, Molokie LB, Talischy N. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood. 2002;99(11):3905-3908. https:\/\/doi.org\/10.1182\/blood.v99.11.3905.","DOI":"10.1182\/blood.v99.11.3905"},{"key":"4860_CR31","doi-asserted-by":"publisher","unstructured":"Rees D, Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, et al. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study. PLoS Med. 2017;14(9):e1002382. https:\/\/doi.org\/10.1371\/journal.pmed.1002382.","DOI":"10.1371\/journal.pmed.1002382"},{"key":"4860_CR32","doi-asserted-by":"publisher","unstructured":"Xuelian Y, Bingying T, Xuan Q, Ning Z, Lin K. A case report of hypothyrotropin hypothyroidism caused by Roxadustat. Med J Peking Union Med Coll Hosp. 2025;16(2):519-522. https:\/\/doi.org\/10.12290\/xhyxzz.2024-0115.","DOI":"10.12290\/xhyxzz.2024-0115"},{"key":"4860_CR33","doi-asserted-by":"publisher","unstructured":"Tokuyama A, Kadoya H, Obata A, Obata T, Sasaki T, Kashihara N. Roxadustat and thyroid-stimulating hormone suppression. Clin Kidney J. 2021;14(5):1472-1474. https:\/\/doi.org\/10.1093\/ckj\/sfab007.","DOI":"10.1093\/ckj\/sfab007"},{"key":"4860_CR34","doi-asserted-by":"publisher","unstructured":"Li C, Georgakopoulou A, Newby GA, Everette KA, Nizamis E, Paschoudi K, et al. In vivo base editing by a single i.V. vector injection for treatment of hemoglobinopathies. JCI Insight. 2022;7(19). https:\/\/doi.org\/10.1172\/jci.insight.162939.","DOI":"10.1172\/jci.insight.162939"},{"key":"4860_CR35","doi-asserted-by":"publisher","unstructured":"Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, et al. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. NEJM Evid. 2021;384(3):205-215. https:\/\/doi.org\/10.1056\/NEJMoa2029392.","DOI":"10.1056\/NEJMoa2029392"},{"key":"4860_CR36","doi-asserted-by":"publisher","unstructured":"Nair R, Li N, Imren S, Kohli P, Lach K, Zhu L, et al. Clinical outcomes among patients with sickle cell disease and transfusion-dependent Beta-thalassemia treated with allogeneic hematopoietic stem cell transplantation: A systematic literature review. J Blood Med. 2025;16:135-150. https:\/\/doi.org\/10.2147\/jbm.S508896.","DOI":"10.2147\/jbm.S508896"},{"key":"4860_CR37","doi-asserted-by":"publisher","unstructured":"Kleinschmidt K, Penkivech G, Troeger A, Foell J, Hanafee-Alali T, Leszczak S, et al. \u03b1\u00df T-cell depleted haploidentical stem cell transplantation for pediatric and young adult patients with transfusion-dependent thalassemia. Bone Marrow Transpl. 2025;60(5):682\u2013689.https:\/\/doi.org\/10.1038\/s41409%2696025%269602546%2696w.","DOI":"10.1038\/s41409%2696025%269602546%2696w"},{"key":"4860_CR38","doi-asserted-by":"publisher","unstructured":"Ma Q, Wyszynski DF, Farrell JJ, Kutlar A, Farrer LA, Baldwin CT, et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J. 2007;7(6):386-394. https:\/\/doi.org\/10.1038\/sj.tpj.6500433.","DOI":"10.1038\/sj.tpj.6500433"},{"key":"4860_CR39","doi-asserted-by":"publisher","unstructured":"M\u00e4kinen S, Sree S, Ala-Nisula T, Kultalahti H, Koivunen P, Koistinen HA. Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men. Diabetologia. 2024;67(9)1943-1954. https:\/\/doi.org\/10.1007\/s00125-024-06185-6.","DOI":"10.1007\/s00125-024-06185-6"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04860-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04860-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04860-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:25:43Z","timestamp":1775820343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04860-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4860"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04860-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the principles of the Declaration of Helsinki. The study protocol was approved by the Medical Ethics Committees of the Second Affiliated Hospital of the Army Medical University (Ref: 2024-Yan-308\u201301) and the Chongqing Hospital of PAP (Ref: WJYY2024-1210). The informed consent forms were obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}